00:30 , Jan 19, 2019 |  BC Extra  |  Company News

Celgene bolsters immuno-metabolism, immune cell toolbox with Kyn, Obsidian deals

Partnerships with Boston area biotechs Kyn Therapeutics Inc. and Obsidian Therapeutics Inc. announced late this week by Celgene Corp. (NASDAQ:CELG) indicate the big biotech is continuing to build its immuno-metabolism and immune cell therapy toolboxes...
13:42 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Organ transplant rejection Mouse studies suggest inhibiting CXCL13, CD40L and ICOSLG, which play roles in B cell maturation and activation, could help treat antibody-mediated lung transplant rejection. In a mouse model of antibody-mediated lung...
19:44 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint in a Phase IIb trial to treat moderate to severe active systemic lupus erythematosus (SLE) in patients receiving...
20:50 , Oct 23, 2018 |  BC Extra  |  Company News

Biogen halts vixotrigine development in painful lumbosacral radiculopathy

Biogen Inc. (NASDAQ:BIIB) will halt development of vixotrigine (BIIB074) for a pain indication after a Phase IIb miss disclosed in the biotech's 3Q18 earnings. Biogen beat total revenue and earnings estimates for the quarter, with...
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Hematology

INDICATION: Hematology Patient sample and mouse studies suggest gene editing of CD40L cDNA in autologous hematopoietic stem cells (HSCs) could help treat X-linked hyper-IgM syndrome (XHIM), which is caused by CD40L mutations. In patient-derived T...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
02:28 , Mar 9, 2018 |  BC Innovations  |  Product R&D

Chips for tox

After several years’ pushing from FDA, NIH and DARPA for more predictive preclinical tox tests, organ-on-a-chip companies are close to demonstrating their models can detect signals missed in animals. While replacing animals is nowhere in...
17:21 , Mar 2, 2018 |  BC Week In Review  |  Company News

MedImmune spins out autoimmune play Viela

The MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN) is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of MedImmune’s Respiratory, Inflammation & Autoimmunity...
16:49 , Feb 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif...
11:06 , Sep 8, 2017 |  BioCentury  |  Product Development

Maximizing neoantigens

In conjunction with raising $55 million in a series B round on Friday, Replimune Group Inc. unveiled details of its Immulytic oncolytic virus platform, including next-generation constructs that underpin the company’s strategy for creating multimodal...